CYCN
Cyclerion Therapeutics, Inc.
$3.48
+0.02 (+0.58%)
At close · Jul 7
Market Cap
$15.07M
Shares
4,330,314
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.48
Open$3.41
Day$3.36–3.48
52W$1.03–8.48
Avg vol 30d27K
Short int48K · 1.1% float · 1.6d
Short vol54%
Last earningsMay 12, 2023
DataJan 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.1 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+58%
above
Price vs 50-day avg
+10%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
33%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+17%
trailing
6-month return
+104%
trailing
YTD return
+174%
this year
Relative strength
+96%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-11% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.11% of float · ▲ +96.3% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Squeeze score
32
low risk · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
EPS growth
+8%
Y/Y
Free cash flow
$-3.3M
Balance sheet
$3.2M
net cash
Quant / Vol
risk profile
Volatility
328%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+58%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
33%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-11% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.11% of float · ▲ +96.3% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $3 · 33%
52-wk high $8
vs 200-day avg +58%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYCN
this stock
Cyclerion Therapeutics, Inc.
|
$15.07M | +174.0% | +3.7% | — | 1.1% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYCN | +3.7% | +16.8% | +103.5% | +2.7% | +174.0% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +2.8% | +15.4% | +96.0% | +2.5% | +164.4% |